ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,303.27
0.12%
US Tech 100
18,062.00
-0.10%
다우존스 지수
40,003.59
0.34%
Bitcoin
66,485.95
0.32%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. OKYO Pharma Ltd (OKYO)

  7. OKYO Pharma Ltd (OKYO) 뉴스

OKYO

OKYO Pharma (OKYO)

OKYO Pharma Ltd
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:OKYO
일자시간출처헤드라인심볼기업
2024/05/0820:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/05/0820:00GlobeNewswire Inc.OKYO Pharma Announces Participation in May 2024 Investor ConferencesNASDAQ:OKYOOKYO Pharma Ltd
2024/04/3020:00GlobeNewswire Inc.OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)NASDAQ:OKYOOKYO Pharma Ltd
2024/04/0908:00GlobeNewswire Inc.OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024NASDAQ:OKYOOKYO Pharma Ltd
2024/04/0220:00GlobeNewswire Inc.OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryNASDAQ:OKYOOKYO Pharma Ltd
2024/03/2220:00GlobeNewswire Inc.OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101NASDAQ:OKYOOKYO Pharma Ltd
2024/03/2120:00GlobeNewswire Inc.OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialNASDAQ:OKYOOKYO Pharma Ltd
2024/03/2020:00GlobeNewswire Inc.OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventNASDAQ:OKYOOKYO Pharma Ltd
2024/02/0921:36InvestorsHub NewsWireOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
2024/02/0921:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/02/0921:00GlobeNewswire Inc.OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
2024/01/3121:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/01/3121:00GlobeNewswire Inc.OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory BoardNASDAQ:OKYOOKYO Pharma Ltd
2024/01/0821:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/01/0821:00GlobeNewswire Inc.OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye DiseaseNASDAQ:OKYOOKYO Pharma Ltd
2024/01/0523:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2024/01/0523:30GlobeNewswire Inc.OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024NASDAQ:OKYOOKYO Pharma Ltd
2023/12/2121:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2023/12/2107:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OKYOOKYO Pharma Ltd
2023/12/1906:56Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2023/12/0421:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2023/12/0421:00GlobeNewswire Inc.OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol VisitNASDAQ:OKYOOKYO Pharma Ltd
2023/11/2921:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2023/11/0205:55Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2023/11/0105:59Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OKYOOKYO Pharma Ltd
2023/10/3120:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2023/10/3120:00GlobeNewswire Inc.OKYO Pharma Announces $5.84 Million Cash Raise and Payables ReductionNASDAQ:OKYOOKYO Pharma Ltd
2023/10/1020:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
2023/10/1000:34InvestorsHub NewsWireOKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain ("NCP")NASDAQ:OKYOOKYO Pharma Ltd
2023/10/0920:00GlobeNewswire Inc.OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)NASDAQ:OKYOOKYO Pharma Ltd
 검색 관련기사 보기:NASDAQ:OKYO

최근 히스토리

COIN
TALUSD
BOV
RAIL3M
RUMO S.A ON
TG
AMZ
Amazon com
COIN
OSMOBTC
Osmosis
COIN
BYKUST
BuyK
EU
HLT
Amundi STOXX Europe 600 ...
LSE
99LR
Orig B Frn29a
BIT
F17326
Vontobel Financial Produ...
USOTC
RDEIY
Redeia Corporacion (PK)
COIN
MBCNTETH
Marblecoin
TG
35V1
VEON
NASDAQ
EYCIE
Eye Care
BIT
P1QLT4
BNP Paribas Issuance
COIN
XVGUST
Verge
COIN
AMSGBP
BIT
S29601
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유